Combined Menin and XPO1 inhibition drive synergistic antileukemic activity in KMT2Ar and NPM1-m AML

This preclinical study demonstrates that combining the menin inhibitor ziftomenib with the XPO1 inhibitor selinexor synergistically suppresses oncogenic transcription and induces apoptosis in KMT2A-rearranged and NPM1-mutated AML by disrupting menin-chromatin interactions, thereby offering a promising strategy to overcome resistance and improve survival outcomes compared to monotherapy.

The Gist

The Big Picture: A Two-Pronged Attack on Leukemia

Imagine the human body as a bustling city. In patients with certain types of leukemia (specifically KMT2A-r and NPM1-m AML), a specific group of "rogue construction crews" has taken over the city's power grid. These crews are forcing the city to build only one thing: more rogue cells, leading to a cancerous explosion.

For a long time, doctors have had a "master key" called a Menin Inhibitor (like a drug called ziftomenib). This key is designed to jam the gears of the main construction crew, stopping them from building more cancer. It works well for many people, but not everyone. Some crews are too strong, or they find a way to sneak around the jammed gear, causing the cancer to come back.

This paper suggests a brilliant new strategy: Don't just jam the gears; cut the power supply too.

The researchers combined the Menin Inhibitor with a second drug called a XPO1 Inhibitor (like selinexor). They found that using these two drugs together doesn't just add their effects; it multiplies them, creating a "synergistic" super-attack that is much stronger than either drug alone.

---

The Characters in Our Story

To understand how this works, let's meet the key players:

1. Menin (The Foreman): Think of Menin as a construction foreman. In healthy cells, he helps organize things. In these specific leukemias, he gets hijacked by a "bad boss" (a fusion protein) and forced to keep the cancer construction crew running 24/7.
2. The Bad Boss (KMT2A-fusion or NPM1-mutant): This is the criminal mastermind holding the foreman hostage, forcing him to turn on the "cancer genes" (like HOXA9 and MEIS1).
3. XPO1 (The Elevator/Transporter): This is a protein that acts like a building's elevator system. It moves things in and out of the cell's control center (the nucleus).
   • The Twist: The researchers discovered that XPO1 isn't just an elevator; it's also the glue that helps the Foreman (Menin) stick to the construction blueprints (DNA). Without XPO1, the Foreman can't hold on to the plans, even if the Bad Boss is still there.

The Strategy: How the Two Drugs Work Together

1. The First Drug (Ziftomenib): The "Key Jammer"

This drug tries to pry the Foreman (Menin) away from the Bad Boss. It's like trying to pull a key out of a lock. It works, but sometimes the Bad Boss is holding on too tight, or the Foreman finds a way to stay attached.

2. The Second Drug (Selinexor): The "Glue Remover"

This drug blocks the elevator system (XPO1). But here is the surprise discovery in this paper: Blocking the elevator also dissolves the glue.
When the researchers blocked XPO1, the Foreman (Menin) suddenly lost his grip on the construction blueprints. He couldn't stick to the DNA anymore, so the cancer construction crew stopped working.

3. The Combination: The "Double Lock"

When you use both drugs:

• Drug A tries to pull the Foreman away.
• Drug B removes the glue holding him to the plans.

The Result: The Foreman is completely useless. The cancer construction crew stops building. The cancer cells realize they can't survive, so they commit "suicide" (a process called apoptosis), and the remaining cells start turning into normal, healthy blood cells (differentiation).

The "Magic" of the Combination

The paper highlights three amazing things about this team-up:

• It's a "Synergy" (1 + 1 = 3): The drugs work better together than the sum of their parts. It's like having a hammer and a screwdriver; using them together fixes the problem much faster than using just one.
• It Spares the Good Guys: When they tested this on normal, healthy stem cells (the "good construction crews"), the drugs didn't hurt them. This is crucial because it means the treatment could stop the cancer without destroying the patient's healthy blood supply.
• It Works in the Real World (Mice): They tested this in mice with human leukemia.
  • Single Drug: The mice lived a bit longer, but the cancer usually came back.
  • Double Drug: The mice lived significantly longer, and in some cases, the cancer was completely wiped out, even at lower doses of the drugs. This suggests fewer side effects for humans.

Why This Matters for Patients

Currently, if a patient takes a Menin inhibitor and the cancer comes back, it's a very difficult situation. This paper suggests that by adding the second drug (XPO1 inhibitor) right from the start, doctors might be able to:

1. Cure more people who wouldn't respond to the single drug.
2. Prevent the cancer from returning by hitting it from two different angles so it can't find a way to escape.
3. Use lower doses of the drugs, which means less nausea, fatigue, and other side effects for the patient.

The Bottom Line

Think of this research as finding a way to defeat a villain who has two layers of armor. The first drug breaks the outer layer, and the second drug shatters the inner layer. Together, they make the villain defenseless.

The researchers are now saying, "We have strong proof in the lab and in mice that this two-drug combination is a game-changer." They are hoping to move this strategy into clinical trials for human patients soon, offering new hope for those with these aggressive types of leukemia.

Technical Summary

1. Problem Statement

Acute Myeloid Leukemia (AML) subtypes driven by KMT2A rearrangements (KMT2A-r) and NPM1 mutations (NPM1-m) rely on the oncogenic transcriptional program driven by the Menin-KMT2A complex. This complex aberrantly activates leukemogenic genes, specifically HOXA9 and MEIS1.

• Current Limitation: While Menin Inhibitors (MIs) like ziftomenib and revumenib have shown efficacy, monotherapy is insufficient for all patients. Resistance mechanisms (e.g., "gatekeeper" mutations in the Menin binding pocket) and short-lived responses remain significant clinical challenges.
• Hypothesis: The authors hypothesized that combining Menin inhibition with XPO1 (Exportin 1) inhibition would synergistically suppress leukemic growth by disrupting the Menin-KMT2A complex and its chromatin occupancy more effectively than either agent alone, potentially overcoming resistance and targeting leukemic stem cells.

2. Methodology

The study employed a comprehensive multi-modal approach combining in vitro mechanistic studies, ex vivo primary cell assays, and in vivo xenograft models.

• Cell Models:
  • Cell Lines: KMT2A-r (MV4;11, MOLM13, SEM) and NPM1-m (OCI-AML3, IMS-M2) AML cell lines.
  • Primary Cells: CD34+ progenitor cells from KMT2A-r and NPM1-m AML patients, as well as normal CD34+ hematopoietic stem/progenitor cells (HSPCs) from healthy donors.
  • Genetically Engineered Models: Mouse myeloid progenitors immortalized by KMT2A/MLLT3 retrovirus; HEK293T cells for co-immunoprecipitation (Co-IP) and mutagenesis studies.
• Pharmacological Agents:
  • Menin Inhibitor: Ziftomenib (clinical-stage).
  • XPO1 Inhibitor: Selinexor (clinical-stage) and KPT-185 (high potency).
• Assays & Techniques:
  • Synergy Analysis: Cell viability (CellTiter-Glo), Combination Index (CI) calculations, and isobolograms.
  • Functional Assays: Apoptosis (Annexin V/PI), Cell Cycle (Flow Cytometry), Colony Forming Unit (CFU) assays for primary cells.
  • Mechanistic Studies:
    • Chromatin Immunoprecipitation (ChIP): To assess Menin and XPO1 occupancy at the HOXA9 locus.
    • Co-Immunoprecipitation (Co-IP): To evaluate protein-protein interactions between Menin, KMT2A/MLLT3, and XPO1.
    • Mutagenesis: Generation of Menin NES (Nuclear Export Signal) mutants to test localization and function.
    • Omics: RNA-sequencing (RNA-seq) and Global Proteomics (TMT-MS) to profile transcriptional and proteomic changes.
  • In Vivo Models:
    • Cell Line-Derived Xenografts (CDX) in NSG mice (MV4;11, OCI-AML3).
    • Patient-Derived Xenografts (PDX) using primary KMT2A-r and NPM1-m AML cells.
    • Dosing regimens included standard and metronomic (low-dose) schedules.

3. Key Contributions & Mechanistic Insights

The paper provides novel mechanistic evidence regarding the interplay between XPO1 and the Menin-KMT2A complex:

• XPO1 Stabilizes Menin-Chromatin Binding: The study reveals that XPO1 is not merely an exporter but is critical for the chromatin occupancy of Menin. Inhibition of XPO1 (via Selinexor or KPT-185) significantly reduced Menin binding to the HOXA9 locus, even without reducing total nuclear Menin levels.
• Disruption of the Ternary Complex: XPO1 inhibition destabilizes the physical interaction between Menin and KMT2A/MLLT3. Co-IP data showed that blocking XPO1 prevents the formation of the stable Menin-KMT2A complex required for oncogenic transcription.
• NES Independence: Experiments with Menin NES mutants demonstrated that while nuclear export is not the primary driver of Menin's transcriptional activity in this context, the interaction with XPO1 (likely via the NES-binding cleft) is essential for Menin to activate target genes like Hoxa9 and Meis1.
• Synergistic Transcriptional Repression: The combination of Ziftomenib and Selinexor produced a more profound downregulation of the HOX/MEIS1 axis and upregulation of differentiation markers (CD11b) than either drug alone.

4. Key Results

• In Vitro Synergy:
  • The combination of Ziftomenib and Selinexor showed synergistic growth inhibition (CI < 1) across all tested KMT2A-r and NPM1-m cell lines.
  • Apoptosis: The combination significantly increased early apoptosis (e.g., 45% in NPM1-m OCI-AML3 vs. ~28% with Selinexor alone).
  • Cell Cycle: Induced G0/G1 arrest and reduced G2/M populations.
• Primary Cell Efficacy & Selectivity:
  • The combination suppressed colony formation in primary KMT2A-r CD34+ cells and induced robust cell death (>50%).
  • Selectivity: Normal CD34+ HSPCs from healthy donors showed no significant toxicity, indicating a therapeutic window.
• Omics Profiling:
  • RNA-seq: The combination downregulated a curated set of Menin/KMT2A target genes (including HOXA9, HOXA10, MEIS1, PBX3) more effectively than monotherapy.
  • Proteomics: Confirmed downregulation of cell cycle regulators (CCNB2, TTK, CDK4) and enrichment of differentiation pathways.
• In Vivo Efficacy:
  • Survival: In CDX and PDX models (both KMT2A-r and NPM1-m), the combination therapy significantly extended survival compared to single agents.
  • Deep Responses: In PDX models, the combination led to a profound reduction in circulating human CD45+ cells and extramedullary infiltration (liver/lung).
  • Durability: Some mice in the combination group remained disease-free for over 6 months (179 days) in PDX models, suggesting potential eradication of leukemic stem cells.
  • Metronomic Dosing: Efficacy was maintained even at reduced doses, suggesting improved tolerability.

5. Significance and Conclusion

This study establishes a strong preclinical rationale for the clinical combination of Menin and XPO1 inhibitors in AML.

• Overcoming Resistance: By targeting two distinct but converging nodes (Menin-KMT2A interaction and XPO1-mediated complex stabilization), the combination may overcome resistance mechanisms that arise from single-agent Menin inhibition (e.g., binding site mutations).
• Novel Mechanism: The discovery that XPO1 is required for Menin's chromatin binding and complex stability offers a new paradigm for understanding leukemogenic transcriptional regulation.
• Translational Potential: The ability to achieve deep, durable responses and target leukemic stem cells while sparing normal hematopoiesis suggests this combination could become a standard of care for KMT2A-r and NPM1-m AML, potentially delaying or preventing relapse.

The authors conclude that simultaneous inhibition of the Menin-KMT2A interaction and XPO1 represents a superior translational strategy to monotherapy, warranting immediate advancement into clinical trials.